Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma.
Niino, M;
Iwabuchi, K;
Kikuchi, S;
Ato, M;
Morohashi, T;
Ogata, A;
Tashiro, K;
Onoé, K;
(2001)
Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma.
Journal of neuroimmunology, 116 (1).
pp. 40-48.
ISSN 0165-5728
DOI: https://doi.org/10.1016/s0165-5728(01)00285-5
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a member of the nuclear hormone receptor superfamily, plays a critical role in adipocyte differentiation and glucose homeostasis. It has been implicated that PPAR-gamma functions as a regulator of cellular proliferation and inflammatory responses. In the present study, we examined whether troglitazone, a selective PPAR-gamma agonists, ameliorated experimental autoimmune encephalomyelitis (EAE) induced by administration of myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 in C57BL/6 mice. We found that troglitazone attenuated the inflammation and decreased the clinical symptoms. It was suggested that the amelioration was attributed to the attenuation of pro-inflammatory cytokine gene expressions.